Applications of botulinum toxin in dentistry: A comprehensive review

Sanjeev Srivastava, Smriti Kharbanda, U S Pal, Vinit Shah, Sanjeev Srivastava, Smriti Kharbanda, U S Pal, Vinit Shah

Abstract

The horizons of treatment options in dentistry are broadening rapidly. In this scenario, applications of unconventional treatment options like use of botulinum toxin (BT) are gaining momentum. The use of BT has been popularly accepted in esthetic procedures like management of facial wrinkles; however, it has been documented to be successful in a variety of conditions. Of particular interest to this paper are applications of BT in the maxillofacial region, concerned to dentistry. BT offers a transient, reversible, relatively safe treatment option to many conditions of interest to a dental practitioner. Dental surgeons by their virtue of being extensively aware of the anatomy of faciomaxillary region are a potential pool of operators who can use BT in their armamentarium with minor skill enhancement and thus widen the perspective of alternative, minimally invasive options to refractory conditions or invasive protocols.

Keywords: Botulinum toxin A; bruxism; gummy smile; temporomandibular joint disorders.

Figures

Figure 1
Figure 1
Schematic representation of botulinum toxin type A injection sites on the face. 1 - Forehead lines: Frontalis muscle, 2 - Glabellar/frown lines: Corrugator supercilii and procerus muscles, 3 - Crow's feet (lateral orbital lines): Orbicularis oculi, 4 - Perioral lines (smoker's lines), gummy smile: Orbicularis oris muscle, 5 - Marionette lines: Depressor anguli oris, 6 - Mentalis dysfunction: Mentalis muscle
Figure 2
Figure 2
Schematic representation of sites for botulinum toxin type A injection in temporomandibular joint

References

    1. Kerner J. Vergiftung durch verdorbene Würste. Tübinger Blätter Naturwissenschaften Arzneykunde. 1817;3:25.
    1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA. 2001;285:1059–70.
    1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–9.
    1. Brin M. Philadelphia: Lippincott Williams & Wilkins; 2000. Botulinum toxin therapy: Basic science and overview of other therapeutic applications. Management of facial lines and wrinkles; pp. 279–302.
    1. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: A report of two cases. J Neurol Neurosurg Psychiatry. 1997;62:198.
    1. Coban A, Matur Z, Hanagasi HA, Parman Y. Iatrogenic botulism after botulinum toxin type A injections. Clin Neuropharmacol. 2010;33:158–60.
    1. Allergan Inc. Full BOTOX® Product Information Including Boxed Warning Irvine, CA2015. [Last updated on 2015 Aug; Last cited on 2015 Oct 12]. Available from: .
    1. Rao LB, Sangur R, Pradeep S. Application of botulinum toxin type A: An arsenal in dentistry. Indian J Dent Res. 2011;22:440–5.
    1. Nayyar P, Kumar P, Nayyar PV, Singh A. Botox: Broadening the horizon of dentistry. J Clin Diagn Res. 2014;8:ZE25–9.
    1. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology. 1999;53:2102–7.
    1. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 2002;126:459–67.
    1. Truong DD, Jost WH. Botulinum toxin: Clinical use. Parkinsonism Relat Disord. 2006;12:331–55.
    1. Laskawi R. The use of botulinum toxin in head and face medicine: An interdisciplinary field. Head Face Med. 2008;4:5.
    1. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4:10.
    1. Frampton JE, Easthope SE. Botulinum toxin A (Botox Cosmetic): A review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4:709–25.
    1. Niamtu J., 3rd Aesthetic uses of botulinum toxin A. J Oral Maxillofac Surg. 1999;57:1228–33.
    1. Niamtu J., 3rd Botulinum toxin A: A review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg. 2003;61:317–24.
    1. Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999;103:645–52.
    1. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. 1994;32:26–8.
    1. Isaac AM. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A. Br J Oral Maxillofac Surg. 2000;38:571–2.
    1. Bentsianov B, Francis A, Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Oper Tech Otolaryngol Head Neck Surg. 2004;15:110–3.
    1. Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:e1–11.
    1. Jaspers GW, Pijpe J, Jansma J. The use of botulinum toxin type A in cosmetic facial procedures. Int J Oral Maxillofac Surg. 2011;40:127–33.
    1. Amin V, Amin V, Swathi D, Ali Jabir D, Shetty P. Enhancing the smile with botox – Case report. Glob J Med Res. 2014;13:15–8.
    1. Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther. 2008;10:35–42.
    1. Hwang WS, Hur MS, Hu KS, Song WC, Koh KS, Baik HS, et al. Surface anatomy of the lip elevator muscles for the treatment of gummy smile using botulinum toxin. Angle Orthod. 2009;79:70–7.
    1. Polo M. Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile) Am J Orthod Dentofacial Orthop. 2008;133:195–203.
    1. Miskinyar SA. A new method for correcting a gummy smile. Plast Reconstr Surg. 1983;72:397–400.
    1. Choi YJ, Kim JS, Gil YC, Phetudom T, Kim HJ, Tansatit T, et al. Anatomical considerations regarding the location and boundary of the depressor anguli oris muscle with reference to botulinum toxin injection. Plast Reconstr Surg. 2014;134:917–21.
    1. Bell WE. Chicago: Year Book Medical Publishers; 1982. Clinical Management of Temporomandibular Disorders.
    1. Okeson JP. Missouri: Elsevier Health Sciences; 2014. Management of Temporomandibular Disorders and Occlusion.
    1. Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache. 2002;42:1033–7.
    1. Kaplan AS, Assael LA, editors. Philadelphia: WB Saunders Company; 1991. Temporomandibular disorders: Diagnosis and treatment; pp. 40–9.
    1. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral Maxillofac Surg. 1999;57:916–20.
    1. Lee KM, Chow J, Hui E, Li W. Botulinum toxin type A injection for the management of myofascial temporomandibular pain disorder. Asian J Oral Maxillofac Surg. 2005;17:100–3.
    1. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002;18(6 Suppl):S198–203.
    1. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007;13:253–60.
    1. Moore AP, Wood GD. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J. 1997;183:415–7.
    1. Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg. 1997;26:458–60.
    1. Fu KY, Chen HM, Sun ZP, Zhang ZK, Ma XC. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg. 2010;48:281–4.
    1. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131:211–6.
    1. Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: An evidence-based review. Int Dent J. 2012;62:1–5.
    1. Lee SJ, McCall WD, Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: A randomized controlled trial. Am J Phys Med Rehabil. 2010;89:16–23.
    1. Shim YJ, Lee MK, Kato T, Park HU, Heo K, Kim ST. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: A polysomnographic evaluation. J Clin Sleep Med. 2014;10:291–8.
    1. Xu H, Shan XF, Cong X, Yang NY, Wu LL, Yu GY, et al. Pre- and post-synaptic effects of botulinum toxin A on submandibular glands. J Dent Res. 2015;94:1454–62.
    1. Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G, et al. Botulinum toxin therapy: A tempting tool in the management of salivary secretory disorders. Am J Otolaryngol. 2008;29:333–8.
    1. Benson J, Daugherty KK. Botulinum toxin A in the treatment of sialorrhea. Ann Pharmacother. 2007;41:79–85.
    1. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg. 2003;61:454–7.
    1. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279–81.
    1. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: A management challenge. Am Fam Physician. 2004;69:2628–34.
    1. Setler PE. Therapeutic use of botulinum toxins: Background and history. Clin J Pain. 2002;18(6 Suppl):S119–24.
    1. Philouze P, Vertu D, Ceruse P. Bilateral gustatory sweating in the submandibular region after bilateral neck dissection successfully treated with botulinum toxin. Br J Oral Maxillofac Surg. 2014;52:761–3.
    1. Beerens AJ, Snow GB. Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg. 2002;89:116–9.
    1. Toffola ED, Furini F, Redaelli C, Prestifilippo E, Bejor M. Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disabil Rehabil. 2010;32:1414–8.
    1. Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 2002;16:705–9.
    1. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, et al. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: A systematic review. J Headache Pain. 2013;14:72.
    1. Guardiani E, Sadoughi B, Blitzer A, Sirois D. A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A. Laryngoscope. 2014;124:413–7.
    1. Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:47–50.
    1. Nishimura K, Itoh T, Takaki K, Hosokawa R, Naito T, Yokota M. Periodontal parameters of osseointegrated dental implants. A 4-year controlled follow-up study. Clin Oral Implants Res. 1997;8:272–8.
    1. Ihde S. Prophylactic use of botulinum toxin in dental implantology. CMF Implement Dir. 2007;1:29–34.
    1. Kayikçioglu A, Erk Y, Mavili E, Vargel I, Ozgür F. Botulinum toxin in the treatment of zygomatic fractures. Plast Reconstr Surg. 2003;111:341–6.
    1. Akbay E, Cevik C, Damlar I, Altan A. Treatment of displaced mandibular condylar fracture with botulinum toxin A. Auris Nasus Larynx. 2014;41:219–21.
    1. Canter HI, Kayikcioglu A, Aksu M, Mavili ME. Botulinum toxin in closed treatment of mandibular condylar fracture. Ann Plast Surg. 2007;58:474–8.
    1. Seok H, Park YT, Kim SG, Park YW. Correction of post-traumatic anterior open bite by injection of botulinum toxin type A into the anterior belly of the digastric muscle: Case report. J Korean Assoc Oral Maxillofac Surg. 2013;39:188–92.
    1. Chow TL, Chan SW, Lam SH. Ranula successfully treated by botulinum toxin type A: Report of 3 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:41–2.
    1. Fu J, Ngo A, Shin K, Bruera E. Botulinum toxin injection and phenol nerve block for reduction of end-of-life pain. J Palliat Med. 2013;16:1637–40.
    1. On AY, Kirazli Y, Kismali B, Aksit R. Mechanisms of action of phenol block and botulinus toxin Type A in relieving spasticity: Electrophysiologic investigation and follow-up. Am J Phys Med Rehabil. 1999;78:344–9.
    1. Laskawi R, Ellies M. The role of botulinum toxin in the management of head and neck cancer patients. Curr Opin Otolaryngol Head Neck Surg. 2007;15:112–6.
    1. Grünheid T, Langenbach GE, Korfage JA, Zentner A, van Eijden TM. The adaptive response of jaw muscles to varying functional demands. Eur J Orthod. 2009;31:596–612.
    1. Kato T, Thie NM, Montplaisir JY, Lavigne GJ. Bruxism and orofacial movements during sleep. Dent Clin North Am. 2001;45:657–84.
    1. Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: A new approach based on the gingival exposure area. J Am Acad Dermatol. 2010;63:1042–51.
    1. Poulain B, Popoff MR, Molgó J. How do the botulinum neurotoxins block neurotransmitter release: From botulism to the molecular mechanism of action. Botulinum J. 2008;1:14–87.
    1. Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 2010;39:197–207.
    1. Naumann M, Jankovic J. Safety of botulinum toxin type A: A systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981–90.
    1. US Food and Drug Administration. Information for healthcare professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). FDA Alert. Rockville, MD: FDA; 2009. Aug,
    1. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34–8.
    1. Katz H. Botulinum toxins in dentistry – The new paradigm for masticatory muscle hypertonicity. Singapore Dent J. 2005;27:7–12.
    1. Hurkadle JK, Jatania A, Shanthraj R, Lakshmi B, Subbiah P, Linga S. Botox: Buy me beauty. J Orofac Res. 2012;2:160–4.
    1. Chen YW, Chiu YW, Chen CY, Chuang SK. Botulinum toxin therapy for temporomandibular joint disorders: A systematic review of randomized controlled trials. Int J Oral Maxillofac Surg. 2015;44:1018–26.
    1. Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2012;4:CD007533.
    1. Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2014;7:CD007533.
    1. Al Hamdan EM, Algheryafi AM, Al-Ghareeb FJ, Ashri NY. Knowledge and attitude of dentists towards the use of botulinum toxin and dermal fillers in dentistry, Riyadh, Saudi Arabia. J Cosmet Laser Ther. 2013;15:46–54.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe